Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ernexa Therapeutics Inc.BTX · Entity 8278 | Chief Scientific Officer | June 28, 2022 | June 30, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ernexa Therapeutics Inc.
Report date June 28, 2022 · Filed June 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,496 |
Ending reported balance
After 2022-06-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-06-28 · Exercise / conversion · Acquired 17,573 · Balance 17,573 F1: Each restricted stock unit converts into one share of common stock. Row 2 · 2022-06-28 · Tax withholding · Disposed 6,077 · Balance 11,496 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 52,717 |
Reported balance
After 2022-06-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-06-28 · Exercise / conversion · Disposed 17,573 · Balance 52,717 F1: Each restricted stock unit converts into one share of common stock. F2: On June 28, 2021, the reporting person was granted 70,290 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit converts into one share of common stock.
F2: On June 28, 2021, the reporting person was granted 70,290 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 28, 2022 Filed Jun 30, 2022 00:01 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | Exercise / conversionRestricted Stock Units · Derivative | 17,573 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-024524 · form4.xml · derivative · entry 3 DAmour Kevin · CIK 0001870486 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,717 Underlying: Common Stock · 17,573 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock. F2 · derivative.exercise_date: On June 28, 2021, the reporting person was granted 70,290 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On June 28, 2021, the reporting person was granted 70,290 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date. Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 00:01 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | Tax withholdingCommon Stock | 6,077 | $0.55 | $3,363.01 |
DisclosureSEC source: 0001140361-22-024524 · form4.xml · nonDerivative · entry 2 DAmour Kevin · CIK 0001870486 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,496 Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 00:01 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | Exercise / conversionCommon Stock | 17,573 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-024524 · form4.xml · nonDerivative · entry 1 DAmour Kevin · CIK 0001870486 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of common stock. Read SEC document |
| March 11, 2022 Filed Mar 16, 2022 01:34 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option (Right to buy) · Derivative | 138,400 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001140361-22-009664 · form4.xml · derivative · entry 1 DAmour Kevin · CIK 0001870486 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,400 Underlying: Common Stock · 138,400 shares Expires 2032-03-11 F1 · derivative.exercise_date: The options vest and become exercisable over three years, with 25% of the options vesting on the one-year anniversary of the grant date and the remaining options vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 11, 2022 Filed Mar 18, 2022 01:00 UTC Amendment | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option (Right to buy) · Derivative | 138,400 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001140361-22-009984 · form4.xml · derivative · entry 1 DAmour Kevin · CIK 0001870486 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,400 Underlying: Common Stock · 138,400 shares Expires 2032-03-11 F1 · derivative.exercise_date: The options vest and become exercisable in 36 substantially equal monthly installments from the grant date. Read SEC document |
| June 28, 2021 Filed Jul 1, 2021 01:34 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantRestricted Stock Unit · Derivative | 70,290 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-023007 · form4.xml · derivative · entry 2 DAmour Kevin · CIK 0001870486 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,290 Underlying: Common Stock · 70,290 shares Expires 2031-06-28 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: The Restricted Stock Unit vests and becomes exercisable in four equal installments on June 28 of each of 2022, 2023, 2024 and 2025, provided they shall vest in full immediately prior to a Change in Control (as defined in Dr. D'Amour's Executive Employment Agreement, dated as of June 5, 2021 and effective as of June 28, 2021), subject to continued service through each vesting date. Read SEC document |
| June 28, 2021 Filed Jul 1, 2021 01:34 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option · Derivative | 140,580 | $0.00 Strike: $21.35 | $0.00 |
DisclosureSEC source: 0001140361-21-023007 · form4.xml · derivative · entry 1 DAmour Kevin · CIK 0001870486 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,580 Underlying: Common Stock · 140,580 shares Expires 2031-06-28 F1 · derivative.exercise_date: The option vests and becomes exercisable over four years, with twenty-five percent of the shares covered thereby vesting on June 28, 2022, and 1/36 of the remaining shares covered thereby vesting on the 28th day of each calendar month from July 28, 2022 through June 28, 2025, subject to continued service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.